Skip to main content

Table 2 Unadjusted and adjusted risk difference between recombinant thrombomodulin use and outcomes among predicted target patients

From: Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries

Predicted target patients

In-hospital mortality

28-day mortality

Unadjusted risk Difference (95% CI)

Adjusted risk difference (95% CI)

Unadjusted risk Difference (95% CI)

Adjusted risk difference (95% CI)

Test set of the derivation cohort (n = 118)

 − 22.0%

(− 40.6 to − 3.4%)

 − 27.4%

(− 41.8 to − 12.9%)

 − 20.0%

(− 38.2 to − 1.8%)

 − 23.6%

(− 39.8 to − 7.4%)

Validation cohort (n = 142)

 − 15.1%

(− 31.1 to 1.0%)

 − 31.3%

(− 53.5 to − 9.1%)

 − 8.4%

(− 24.7 to 8.0%)

 − 21.1%

(− 43.4 to 1.1%)

  1. In the test set of derivation cohort, the adjusted variables were age, sex, comorbidities, and Sequential Organ Failure Assessment (SOFA) scores
  2. In the validation cohort, the adjusted variables were age, sex, comorbidities, SOFA scores, and in-hospital management, including renal replacement therapy, and treatment with steroids, intravenous immunoglobulin, antithrombin, and vasopressors
Back to article page

Critical Care

ISSN: 1364-8535